Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag Olamine for PARPi-induced thrombocytopenia
ChiCTR2400088126Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in Thrombocytopenia and ovarian cancer, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Platelet count. Started May 2023; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopeniaovarian cancer
Beyond the preview
Go deeper on ChiCTR2400088126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088126.